Patent application number | Description | Published |
20120172380 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT - The invention relates to substituted 4-(tetrazol-5-yl)-quinazoline derivatives of the formula-I, | 07-05-2012 |
20120329810 | IMATINIB MESYLATE ORAL PHARMACEUTICAL COMPOSITION AND PROCESS FOR PREPARATION THEREOF - The invention relates to an oral pharmaceutical composition comprising, greater than 80% of Imatinib, by weight based on the total weight of the composition and the process for preparation thereof. | 12-27-2012 |
20130059889 | ANHYDROUS LENALIDOMIDE FORM-I - Anhydrous polymorphic form-I of anti cancer drug, Lenalidomide whose chemical name is 3-(4-amino-1-oxo-1,3-dihydro-isoindole-2-yl)-piperidine-2,6-dione, is disclosed. Alternate methods for making anhydrous polymorphic form-I of Lenalidomide are also disclosed. | 03-07-2013 |
20130060030 | PROCESS FOR THE PREPARATION OF HIGHLY PURE CRYSTALLINE IMATINIB BASE - A process for the preparation of highly pure crystalline imatinib base form- N of Formula (I) is disclosed. Imatinib base of this invention is suitable for conversion to pharmaceutically acceptable salts. | 03-07-2013 |
20130172571 | PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE - Disclosed is a process for the preparation of Ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate (I) the key intermediate for the preparation of [2-[3-cyano-4-(2-Methyl-propoxy)phenyl]-4-methyl-5-thiazole carboxylic acid (Febuxostat, I(A)) is approved under the trademark Uloric® by the US Food and Drug Administration for the treatment of hyperuricemia and gouty arthritis. | 07-04-2013 |
20130184490 | PROCESS TO PREPARE S-2-HYDROXY-3-METHOXY-3,3-DIPHENYL PROPIONIC ACID - Disclosed is a process for the preparation of S-2-Hydroxy-3-methoxy-3,3-diphenylpropionic acid (I) the key intermediate for the preparation of Ambrisentan [(+)-2(S)-(4,6-Dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid]. Ambrisentan of the formula (IA) is approved under the trademark “Letairis ®” by the US Food and Drug Administration for the treatment of Pulmonary artery hypertension (PAH). | 07-18-2013 |
20130245259 | PROCESS FOR THE PREPARATION OF BOSENTAN MONOHYDRATE - The invention relates to improved processes for the preparation of bosentan monohydrate which provide higher yield and purity. | 09-19-2013 |
20140121245 | ANHYDROUS LENALIDOMIDE FORM-I - Anhydrous polymorphic form-I of anti cancer drug, Lenalidomide whose chemical name is 3-(4-amino-1-oxo-1,3-dihydro-isoindole-2-yl)-piperidine-2,6-dione, is disclosed. Alternate methods for making anhydrous polymorphic form-I of Lenalidomide are also disclosed. | 05-01-2014 |